PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference
01 Novembre 2022 - 12:00PM
Business Wire
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
changing the treatment paradigm for devastating diseases, today
announced that Bharatt Chowrira, Ph.D., J.D., President and Chief
Business, Finance and Operating Officer, and Julie Krop, M.D.,
Chief Medical Officer, will participate in a fireside chat at the
Credit Suisse 31st Annual Healthcare Conference in Rancho Palos
Verdes, CA, on Tuesday, November 8, 2022, at 12:50pm PST / 3:50pm
EST. A webcast of the presentation will be available at
https://investors.puretechhealth.com.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20221101005203/en/
PureTech’s Bharatt Chowrira, Ph.D., J.D.,
President and Chief Business, Finance and Operating Officer, and
Julie Krop, M.D., Chief Medical Officer, will participate in a
fireside chat at the Credit Suisse 31st Annual Healthcare
Conference in Rancho Palos Verdes, CA, on Tuesday, November 8,
2022, at 12:50pm PST/3:50pm EST (Graphic: Business Wire)
About PureTech Health PureTech is a biotherapeutics
company dedicated to changing the treatment paradigm for
devastating diseases. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
is comprised of 27 therapeutics and therapeutic candidates,
including two that have received both U.S. FDA clearance and
European marketing authorization and a third that will soon be
filed for FDA approval, as of the date of PureTech's most recently
filed Half-Year Report and corresponding Form 6-K. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on unique insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements This
press release contains statements that are or may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those related to our upcoming presentation at
the Credit Suisse Healthcare Conference and our future prospects,
developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks, uncertainties and other important factors that could cause
actual results, performance and achievements to differ materially
from current expectations, including, but not limited to, those
risks, uncertainties and other important factors described under
the caption "Risk Factors" in our Annual Report on Form 20-F for
the year ended December 31, 2021 filed with the SEC and in our
other regulatory filings. These forward-looking statements are
based on assumptions regarding the present and future business
strategies of the Company and the environment in which it will
operate in the future. Each forward-looking statement speaks only
as at the date of this press release. Except as required by law and
regulatory requirements, we disclaim any obligation to update or
revise these forward-looking statements, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221101005203/en/
PureTech Public Relations
publicrelations@puretechhealth.com Investor Relations
IR@puretechhealth.com EU Media Ben Atwell, Rob Winder +44
(0) 20 3727 1000 ben.atwell@FTIconsulting.com U.S. Media
Nichole Sarkis +1 774 278 8273
nichole@tenbridgecommunications.com
PureTech Health (NASDAQ:PRTC)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
PureTech Health (NASDAQ:PRTC)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024